Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Followed by Combination Therapy with Dabrafenib and Trametinib for Metastatic Melanoma
CAS Number: 1922098-69-8
110(6):2140-7
Division of labour between Myc and G1 cyclins in cell cycle commitment and pace control
Houghton PJ
Poziotinib l (chloride) Followed by Combination Therapy withPoziotinib , also known as HM781 36B and NOV120101, is an orally bioavailable, quinazoline based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity. HM781 36B irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. EGFRs, cell surface receptor tyrosine kinases, are often upregulated in a
US$ 44.95
US$ 44.95
US$ 43.85